Endonovo Therapeutics Inc Revenue Growth Rates (ENDV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Endonovo Therapeutics Inc   (ENDV)
 

ENDV's Revenue Growth by Quarter and Year

Endonovo Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENDV Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.05
1st Quarter March 0.09
FY 0.14

ENDVs Annual Revenue
Endonovo Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.14 millions
Endonovo Therapeutics Inc 's Revenue in the fiscal year 2021 $ 0.07 millions
Endonovo Therapeutics Inc 's Revenue in the fiscal year 2020 $ 0.17 millions
Endonovo Therapeutics Inc 's Revenue in the fiscal year 2019 $ 0.31 millions
Endonovo Therapeutics Inc 's Revenue in the fiscal year 2018 $ 0.08 millions




ENDV Revenue third quarter 2023 Y/Y Growth Comment
Endonovo Therapeutics Inc reported drop in Revenue in the third quarter 2023 by -84.8% to $ 0.00 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Endonovo Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue no change of 0%.

According to the results reported in the third quarter 2023, Endonovo Therapeutics Inc achieved the best Revenue growth in Medical Equipment & Supplies industry. While Endonovo Therapeutics Inc ' s Revenue meltdown of -84.8% ranks overall at the positon no. in the third quarter 2023.


ENDV Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - - - -93.33 %
3rd Quarter September -84.8 % 0 % -75 % -20 %
2nd Quarter June - - -25 % -33.33 %
1st Quarter March - - -57.14 % 75 %
FY   - 85.71 % -56.25 % -

Financial Statements
Endonovo Therapeutics Inc 's third quarter 2023 Revenue $ 0.00 millions ENDV's Income Statement
Endonovo Therapeutics Inc 's third quarter 2022 Revenue $ 0.01 millions Quarterly ENDV's Income Statement


ENDV Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 1100 % - -75 %
3rd Quarter September -96.96 % - -66.67 % 0 %
2nd Quarter June -44.44 % - 0 % -42.86 %
1st Quarter March -25 % - 200 % -53.33 %
FY (Year on Year)   - 85.71 % -56.25 % -


Back to ENDV Growth rate Comparisons >> Back to ENDV Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Jun 30 2023)   (Jun 30 2022)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Jun 30 2023)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Endonovo Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENDV's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Endonovo Therapeutics Inc come out even worse considering the 0.05 millions a quarter before.

Within Medical Equipment & Supplies industry Endonovo Therapeutics Inc achieved highest sequential Revenue growth. While Endonovo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENDV's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Endonovo Therapeutics Inc come out even worse considering the 0.05 millions a quarter before.

Within Medical Equipment & Supplies industry Endonovo Therapeutics Inc achieved highest sequential Revenue growth. While Endonovo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Endonovo Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 0.26 $ 0.27 $ 0.22 $ 0.14 $ 0.01
Y / Y Revenue Growth (TTM) 1699.85 % 2302.27 % 442.42 % 85.15 % -83.14 %
Year on Year Revenue Growth Overall Ranking # 3645 # 3774 # 3210 # 3486 # 2995
Seqeuential Revenue Change (TTM) -3.56 % 20.19 % 62.99 % 852.67 % 28.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 616 # 3746 # 3107 # 3355 # 189


Cumulative Revenue growth Comment
Assuming the Endonovo Therapeutics Inc 's fiscal year would have ended in Sep 30 2023, Endonovo Therapeutics Inc would have reprted above average annual Revenue surge of 1699.85% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 2302.27% surge in Jun 30 2023.

In the Healthcare sector 548 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3645, from total ranking in previous quarter at 3774.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 40
Healthcare Sector # 549
Overall # 3645

Revenue TTM Y/Y Growth Statistics
High Average Low
2302.27 %
 307.93 %
-92.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 168
S&P 500 # 616
Cumulative Revenue growth Comment
Assuming the Endonovo Therapeutics Inc 's fiscal year would have ended in Sep 30 2023, Endonovo Therapeutics Inc would have reprted above average annual Revenue surge of 1699.85% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 2302.27% surge in Jun 30 2023.

In the Healthcare sector 548 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3645, from total ranking in previous quarter at 3774.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 40
Healthcare Sector # 549
Overall # 3645

Revenue TTM Y/Y Growth Statistics
High Average Low
2302.27 %
307.93 %
-92.62 %
 






Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENDV's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Adaptimmune Therapeutics Plc-0.16%$ -0.164 millions
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Vycor Medical Inc -0.44%$ -0.442 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Hologic Inc-0.81%$ -0.808 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions


About Endonovo Therapeutics Inc Revenue Growth Rates (ENDV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Endonovo Therapeutics Inc (CIK 1528172).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-23-046561
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Endonovo Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.